Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18116301 | 0.83 | KDM6B (0.51) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL3051612 | 0.82 | KDM6B (0.50) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL17038777 | 0.81 | CA12 (0.47) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL17037043 | 0.81 | KDM6B (0.46) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL25097470 | 0.80 | CA12 (0.46) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL19755641 | 0.80 | FPR2 (0.50) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL17034776 | 0.78 | FPR2 (0.48) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL19487142 | 0.78 | CA12 (0.59) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL25097162 | 0.76 | CA12 (0.43) | KDM6BKDM4AKDM5ACA12CA1 | |
| SCHEMBL13417441 | 0.74 | HPGDS (0.52) | ALDH1A1HPGDSLMNAEPHX2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795568-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3265456-B1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-8633231-B2 | Substituted imidazolones, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2013-05-16 | — | — | US | disclosed |
| US-8361959-B2 | Spiro-imidazolone derivatives as glucagon receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130012493-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012493-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | KDM6B 4431/4885KDM4A 4417/4885KDM5A 4642/4885 |
| US-20130123315-A1 | SUBSTITUTED IMIDAZOLONES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | UGT2B7, CYP3A43, UGT1A7 | KDM6B 2917/4885KDM4A 2547/4885KDM5A 2102/4885 |
| US-20130012434-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | KDM6B 4161/4885KDM4A 4026/4885KDM5A 4586/4885 |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GCGR, GIPR | KDM6B 4567/4885KDM4A 4447/4885KDM5A 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.